GANX
NASDAQ
US
Gain Therapeutics, Inc. - Common Stock
$1,85
▼ $-0,09
(-4,64%)
Vol. 521K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$123.8M
ROE
-222,6%
Margine
-6393,8%
D/E
7,18
Beta
0,03
52W
$1–$4
Consenso Wall Street
11 analisti · Apr 20264
Acquisto forte
6
Compra
1
Mantieni
0
Vendi
0
Vendita forte
90,9%
Rating Compra
Grafico dei Prezzi
Titoli simili
HURA
TuHURA Biosciences Inc
$45.9M
ANIX
Anixa Biosciences Inc
$102.7M
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28,5
$113.6M
INO
Inovio Pharmaceuticals Inc
$119.5M
SERA
Sera Prognostics Inc
$113.9M
COEP
Coeptis Therapeutics Holdings Inc
$76.1M
XGN
Exagen Inc
$137.8M
EXOZ
eXoZymes Inc
$91.4M
Utili
Tasso di battuta: 80,0%
Prossimo report
Mag 12, 2026
Stima EPS: $-0,14
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,14 | — | — |
| Dic 2025 | $-0,15 | $-0,11 | +$0,04 |
| Set 2025 | $-0,15 | $-0,15 | +$0,00 |
| Giu 2025 | $-0,17 | $-0,19 | $-0,02 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$4.5M | -$3.8M | -$4.5M | -$5.8M | -$5.3M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -222.6% | -222.6% | -222.6% | -222.6% | -222.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -6393.8% | -6393.8% | -6393.8% | -6393.8% | -6393.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 12.21 | 12.21 | 12.21 | 12.21 | 7.18 | 7.18 |
| Current Ratio | 1.79 | 1.79 | 1.79 | 1.79 | 2.52 | 2.52 |
Rapporti chiave
ROA (TTM)
-135,5%
P/S (TTM)
774,05
P/B
7,6
EPS (TTM)
$-0,95
CF/Share
$-1,43
52W High
$4,34
52W Low
$1,41
$1,41
Intervallo 52 settimane
$4,34
Salute finanziaria
Flusso di cassa libero
-$4.9M
Debito netto
-$8.2M
Liquidità
$8.8M
Debito totale
$605K
Aggiornato al Set 30, 2025
Як GANX виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка GANX vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
774,1
▲
5924%
sopra
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
7,6
▲
211%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість GANX vs аналоги Biotechnology
ROE
-222,6%
▼
231%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-6393,8%
▼
2130%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-135,5%
▼
190%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя GANX vs аналоги Biotechnology
D/E ratio
7,2
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
2,5
▼
43%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,0
▼
97%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів GANX
GANX
Mediana peer
Industria
GANX прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
GANX vs аналоги: ключові метрики
Principali azionisti
Top 5: 12,04%Marshall Wace LLP
4,32%
$3.0M
Potomac Capital Management,…
2,63%
$1.8M
Jones Financial Companies, …
1,83%
$1.3M
Susquehanna International G…
1,78%
$1.3M
Vanguard Group Inc
1,48%
$1.0M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora